These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37348739)

  • 1. Olanzapine for Non-Chemotherapy Related Nausea and Emesis in Patients with a Palliative Care Consult.
    Bonar S; Schneider HL; Cook K; Samala RV; Poole MFF
    J Pain Symptom Manage; 2023 Oct; 66(4):e455-e459. PubMed ID: 37348739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients.
    Fonte C; Fatigoni S; Roila F
    Crit Rev Oncol Hematol; 2015 Aug; 95(2):214-21. PubMed ID: 25779971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olanzapine as a rescue antiemetic in hematopoietic stem cell transplant.
    Monson T; Greer D; Kreikemeier E; Liewer S
    J Oncol Pharm Pract; 2020 Jun; 26(4):918-922. PubMed ID: 31635549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olanzapine as antiemetic drug in oncology: a retrospective study in non-responders to standard antiemetic therapy.
    Slimano F; Netzer F; Borget I; Lemare F; Besse B
    Int J Clin Pharm; 2018 Oct; 40(5):1265-1271. PubMed ID: 29744791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re: "Olanzapine for Nonchemotherapy Related Nausea and Emesis in Patients With a Palliative Care Consult".
    Lowry MF
    J Pain Symptom Manage; 2024 Jan; 67(1):e113. PubMed ID: 37611880
    [No Abstract]   [Full Text] [Related]  

  • 6. A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center.
    Aseeri M; Mukhtar A; Al Khansa S; Elimam N; Jastaniah W
    J Oncol Pharm Pract; 2013 Jun; 19(2):138-44. PubMed ID: 23034405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Risk of QTc Prolongation with Antiemetics in the Palliative Care Setting: A Narrative Review.
    Gavioli EM; Guardado N; Haniff F; Deiab N; Vider E
    J Pain Palliat Care Pharmacother; 2021 Jun; 35(2):125-135. PubMed ID: 33974499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Olanzapine for Symptom Relief in Cancer Patients.
    Nakagawa N; Suzuki M
    J Pain Palliat Care Pharmacother; 2022 Dec; 36(4):216-222. PubMed ID: 36250742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olanzapine for the Treatment of Advanced Cancer-Related Chronic Nausea and/or Vomiting: A Randomized Pilot Trial.
    Navari RM; Pywell CM; Le-Rademacher JG; White P; Dodge AB; Albany C; Loprinzi CL
    JAMA Oncol; 2020 Jun; 6(6):895-899. PubMed ID: 32379269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine.
    Bosnjak SM; Dimitrijevic J; Djordjevic F
    Curr Opin Support Palliat Care; 2016 Jun; 10(2):180-8. PubMed ID: 27028050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of olanzapine as an antiemetic in palliative medicine: a systematic review of the literature.
    Saudemont G; Prod'Homme C; Da Silva A; Villet S; Reich M; Penel N; Gamblin V
    BMC Palliat Care; 2020 Apr; 19(1):56. PubMed ID: 32321488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults.
    Sutherland A; Naessens K; Plugge E; Ware L; Head K; Burton MJ; Wee B
    Cochrane Database Syst Rev; 2018 Sep; 9(9):CD012555. PubMed ID: 30246876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study.
    Mizukami N; Yamauchi M; Koike K; Watanabe A; Ichihara K; Masumori N; Yamakage M
    J Pain Symptom Manage; 2014 Mar; 47(3):542-50. PubMed ID: 23856100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olanzapine in oncology palliative care.
    Šoukalová Z
    Klin Onkol; 2022; 35(4):276-283. PubMed ID: 35989084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olanzapine (5 mg) plus standard triple antiemetic therapy for the prevention of multiple-day cisplatin hemotherapy-induced nausea and vomiting: a prospective randomized controlled study.
    Gao J; Zhao J; Jiang C; Chen F; Zhao L; Jiang Y; Li H; Wang W; Wu Y; Jin Y; Da L; Liu G; Zhang Y; Li H; Zhang Z; Jin G; Li Q
    Support Care Cancer; 2022 Jul; 30(7):6225-6232. PubMed ID: 35449368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis.
    Yokoe T; Hayashida T; Nagayama A; Nakashoji A; Maeda H; Seki T; Takahashi M; Takano T; Abe T; Kitagawa Y
    Oncologist; 2019 Jun; 24(6):e347-e357. PubMed ID: 30333194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting.
    Navari RM
    Expert Opin Drug Saf; 2016; 15(3):343-56. PubMed ID: 26699406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial.
    Clemmons AB; Orr J; Andrick B; Gandhi A; Sportes C; DeRemer D
    Biol Blood Marrow Transplant; 2018 Oct; 24(10):2065-2071. PubMed ID: 29906570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary and cumulative meta-analysis of olanzapine for antiemetic prophylaxis for chemotherapy-induced nausea and vomiting: do we still need to study its effectiveness?
    Chiu L; Chow R; DeAngelis C; Lock M; Simone CB
    Ann Palliat Med; 2021 Mar; 10(3):2540-2547. PubMed ID: 33440973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy.
    Nakashima K; Murakami H; Yokoyama K; Omori S; Wakuda K; Ono A; Kenmotsu H; Naito T; Nishiyama F; Kikugawa M; Kaneko M; Iwamoto Y; Koizumi S; Mori K; Isobe T; Takahashi T
    Jpn J Clin Oncol; 2017 Sep; 47(9):840-843. PubMed ID: 28633504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.